Replies to post #33061 on Humanigen Inc (HGENQ)

[JPG77]

The FDA's statement to HGEN says everything we need to know. In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19. HGEN's treatment has known risks that the FDA doesn't like, unlike Leronlimab that has no SAEs.